US HB5444 | 2019-2020 | 116th Congress

Status

Spectrum: Bipartisan Bill
Status: Introduced on December 17 2019 - 25% progression, died in committee
Action: 2019-12-18 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]

Summary

To amend the Biologics Price Competition and Innovation Act of 2009 to streamline the transition of certain products from approval as a drug to licensure as a biological product, and for other purposes.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Lower Insulin Costs Now Act

Sponsors


History

DateChamberAction
2019-12-18HouseReferred to the Subcommittee on Health.
2019-12-17HouseReferred to the House Committee on Energy and Commerce.
2019-12-17HouseIntroduced in House

Same As/Similar To

HB19 (Related) 2019-12-19 - Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
SB1895 (Related) 2019-07-08 - Placed on Senate Legislative Calendar under General Orders. Calendar No. 133.
SB2103 (Related) 2019-07-11 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S4809)
HB6155 (Related) 2020-03-09 - Referred to the House Committee on Energy and Commerce.
HB1865 (Related) 2019-12-20 - Became Public Law No: 116-94. (TXT | PDF)

Subjects


US Congress State Sources


Bill Comments

feedback